TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3123092
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of encainide therapy
Study: 3123092
Drug: ODE infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ODE infusion
Study: 3123092
Drug: 3MODE infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3MODE infusion
Study: 31976311
Drug: FMT-L
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMT-L
Study: 23042922
Drug: Single-dose gadobenate
Normalized name: gadobenate
DrugBank: Gadobenic acid (DB00743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose gadobenate dimeglumine
Study: 23042922
Drug: Double-dose gadopentetate
Normalized name: gadopentetate
DrugBank: Gadopentetic acid (DB00789)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose gadopentetate dimeglumine
Study: 19815913
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg once daily for 14 days)
Study: 19815913
Drug: Comparator (doxycycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator (doxycycline 100 mg twice daily + metronidazole 400 mg three times daily for 14 days + single 500 mg ciprofloxacin dose)
Study: 12602538
Drug: Atorvastatin (T2DA)
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin (T2DA)
Study: 8813038
Drug: Zidovudine alone
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine alone (600 mg)
Study: 8813038
Drug: Zidovudine plus
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine plus didanosine (600 mg + 400 mg)
Study: 8813038
Drug: Zidovudine plus
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine plus zalcitabine (600 mg + 2.25 mg)
Study: 8813038
Drug: Didanosine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine alone (400 mg)
Study: 1363986
Drug: Sulfasalazine, daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine, daily dosage of 2 g
Study: 3591726
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A capsule (200,000 IU)
Study: 25850817
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (where intravascular injections did not occur)
Study: 19542686
Drug: Regular intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular intake of multivitamin supplement 5 years before diagnosis
Study: 16410483
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (dalteparin; 100 IU/kg BID)
Study: 9440362
Drug: Maximal onset
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal onset principle (e.g., MAR-KET)
Study: 9440362
Drug: Stress principle
Normalized name: Muguettine principle
DrugBank: Hydroxycitronellal (DB14187)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress principle (e.g., MARK-ET)
Study: 3065687
Drug: IFN alpha‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN alpha‐2b at 1 x 10(6) U twice a week (maintenance therapy)
Study: 3065687
Drug: IFN alpha‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN alpha‐2b at 2 x 10(6) U once weekly (maintenance therapy)
Study: 31887617
Drug: Pomegranate juice
Normalized name: pomegranate juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate juice and tablets
Study: 31887617
Drug: Placebo-matching juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching juice and tablets
Study: 21198431
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) + zidovudine (ZDV) + lamivudine (3TC) triple therapy
Study: 12763982
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg (group A)
Study: 11785865
Drug: Medication trolley
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication trolley at the patient's bedside
Study: 3798631
Drug: Flutamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (250 mg X 3)
Study: 3798631
Drug: Estramustine (280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estramustine (280 mg X 2)
Study: 19522391
Drug: Liqi decoction
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liqi decoction (oral for 2 to 3 days)
Study: 2824707
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (1,200 mg/m2), doxorubicin (70 mg/m2), and vincristine (1 mg/m2) (HDCAV)
Study: 2824707
Drug: Conventional-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose cyclophosphamide (1,000 mg/m2), doxorubicin (40 mg/m2), and vincristine (1 mg/m2) (CDCAV)
Study: 10155051
Drug: Aerosolized albuterol
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized albuterol and cromolyn sulfate
Study: 10155051
Drug: Home aerosol
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home aerosol treatments after intramuscular injection of dexamethasone
Study: 6369456
Drug: Chlorpropamide (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpropamide (single dose)
Study: 22075273
Drug: Walnut-enriched diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut-enriched diet (48 g/d for 4 days)
Study: 19412190
Drug: Topical nitroglycerin
Normalized name: nitroglycerin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nitroglycerin formulation
Study: 19412190
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment options
Study: 15197669
Drug: Arndt bronchial
Normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arndt bronchial blocker (BB)
Study: 11967497
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined hormone replacement therapy (E(2)/NETA)
Study: 9717036
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg sublingual 17 beta-oestradiol
Study: 9717036
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg buccal nitroglycerine
Study: 3400639
Drug: AST-120 (3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST-120 (3.2 to 7.2 g/d) administered for 2.4 to 30.1 months (mean 13.2 +/- 7.4 months)
Study: 3400639
Drug: AST-120 (3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST-120 (3.2 to 7.2 g/d)
Study: 29419341
Drug: Self-reported use
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported use of other substances (heroin, cocaine, opiates, oxycodone, benzodiazepines, methamphetamine, phencyclidine, barbiturates)
Study: 18226671
Drug: 91-day extended-regimen
Normalized name: benzphetamine hydrochloride Oral Tablet [Regimex]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 91-day extended-regimen oral contraceptive (OC) with low-dose ethinyl estradiol (EE)
Study: 16607146
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (omeprazole, clarithromycin, amoxicillin for 10 days)
Study: 16607146
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (omeprazole, amoxicillin, metronidazole, bismuth citrate for 10 days)
Study: 12565981
Drug: Wide local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wide local excision (WLE) and tamoxifen (T) 20 mg daily
Study: 11004045
Drug: Enalaprilat 1.25
Normalized name: enalaprilat 1.25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat 1.25 mg IV followed by multidose nicardipine 2 mg IV
Study: 11004045
Drug: Enalaprilat 1.25
Normalized name: enalaprilat 1.25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat 1.25 mg IV followed by labetalol 5 mg IV
Study: 31888742
Drug: FKB327 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: FKB327 40 mg via prefilled syringe (PFS)
Study: 31888742
Drug: FKB327 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: FKB327 40 mg via auto-injector (AI)
Study: 31888742
Drug: FKB327 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: FKB327 40 mg via vial with disposable syringe
Study: 24158488
Drug: Microbicide gel
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microbicide gel adherence in women with ongoing partners
Study: 24158488
Drug: Microbicide gel
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microbicide gel adherence in women with new partners
Study: 24158488
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of both gel and condom in women with new partners
Study: 24158488
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of both gel and condom in women with ongoing partners
Study: 24158488
Drug: High gel
Normalized name: Tegaderm High Gelling Alginate Dressing 4 inches x 4 inches
Approvals — FDA: no, EMA: no, PMDA: no
Description: High gel adherence in women with ongoing partners
Study: 22701339
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion at a target organ concentration of 2.0 ng/mL
Study: 20419581
Drug: Child-focused cognitive
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child-focused cognitive behavior therapy (CBT) plus parental anxiety management (PAM)
Study: 20419581
Drug: Child-focused cognitive
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child-focused cognitive behavior therapy (CBT)
Study: 7755384
Drug: C/MF group
Approvals — FDA: no, EMA: no, PMDA: no
Description: C/MF group (Amiparen, 600-800 mL/day)
Study: 2304739
Drug: Aspirin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (1000 mg three times a day)
Study: 2304739
Drug: Glucamethacin (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucamethacin (140 mg three times a day)
Study: 2304739
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and Glucamethacin
Study: 2304739
Drug: Aspirin, Glucamethacin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, Glucamethacin, and Placebo
Study: 23615154
Drug: Movement Music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Movement Music Therapy (MMT)
Study: 19075278
Drug: Immediate docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate docetaxel (75 mg/m² on day 1 every 21 days, maximum of six cycles)
Study: 8302672
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate 25 mg/kg
Study: 8302672
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate 50 mg/kg
Study: 8302672
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate 70 mg/kg
Study: 8302672
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate doses (25 mg/kg vs 70 mg/kg)
Study: 3119689
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate (single-dose pretreatment)
Study: 3119689
Drug: Terbutaline (single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (single-dose pretreatment, beta 2-agonist)
Study: 9862408
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo nasal spray
Study: 12417369
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin intervention regimen (folic acid, vitamins B(6) and B(12))
Study: 12417369
Drug: Low-dose vitamin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vitamin intervention regimen (folic acid, vitamins B(6) and B(12))
Study: 7742759
Drug: Vancomycin prophylaxis
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin prophylaxis (500 mg x 3 peri-operatively)
Study: 2045037
Drug: Metronidazole 400
Normalized name: metronidazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 400 mg vaginal tablet (2 x 1) for five consecutive days
Study: 25841136
Drug: Mean UFH
Normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean UFH dose difference
Study: 21067893
Drug: Anterior capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior capsule relaxing incisions with neodymium:YAG laser
Study: 19807985
Drug: Original azelastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original azelastine nasal spray, 2 sprays/nostril b.i.d.
Study: 19807985
Drug: Reformulated azelastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reformulated azelastine nasal spray, 2 sprays/nostril b.i.d.
Study: 19807985
Drug: Placebo, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 2 sprays/nostril b.i.d.
Study: 19807985
Drug: Original azelastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original azelastine nasal spray, 1 spray/nostril b.i.d.
Study: 19807985
Drug: Reformulated azelastine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reformulated azelastine, 1 spray/nostril b.i.d.
Study: 17702725
Drug: B cell‐driven
Approvals — FDA: no, EMA: no, PMDA: no
Description: B cell‐driven treatment
Study: 17702725
Drug: Standard protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard protocol of four weekly doses of 375 mg/m2
Study: 15500669
Drug: 20% SLS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% SLS solution applied to scalp
Study: 15500669
Drug: 20% SLS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% SLS solution applied to back
Study: 15500669
Drug: 20% SLS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% SLS solution applied to arm
Study: 9759942
Drug: Ranitidine effervescent
Normalized name: ranitidine Effervescent Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine effervescent formulation
Study: 9759942
Drug: Ranitidine standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine standard formulation
Study: 7995270
Drug: Other ACE
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other ACE inhibitors
Study: 22282300
Drug: Milk with
Normalized name: BETTERMILK with Glytactin 10PE Powder for Suspension (Orange Creme)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk with 250 mg calcium daily
Study: 22282300
Drug: Soymilk with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soymilk with 250 mg calcium daily
Study: 18355422
Drug: Rosuvastatin 40
Normalized name: rosuvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 40 mg plus 20 mL antacid suspension taken simultaneously
Study: 18355422
Drug: Rosuvastatin 40
Normalized name: rosuvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 40 mg plus 20 mL antacid suspension taken 2 h after rosuvastatin
Study: 12848771
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg pseudoephedrine hydrochloride
Study: 30820338
Drug: Propofol target-controlled
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol target-controlled infusion (TCI)
Study: 31082916
Drug: Surgical resection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical resection of the primary tumor followed by systemic therapy (Arm A)
Study: 31082916
Drug: Primary systemic
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary systemic therapy (Arm B)
Study: 29231360
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with western medicine (needle‐medicine group)
Study: 29231360
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine alone (medicine group)
Study: 22050786
Drug: Sitagliptin 50
Normalized name: SITagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 50 mg + Metformin 1000 mg b.i.d.
Study: 22050786
Drug: Sitagliptin 50
Normalized name: SITagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 50 mg + Metformin 500 mg b.i.d.
Study: 22050786
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Sitagliptin + Metformin)
Study: 15149480
Drug: Recent mental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recent mental health or addictions treatment utilization
Study: 9585285
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine (3 microg/kg)
Study: 9585285
Drug: Oral temazepam
Normalized name: Temazepam
DrugBank: Temazepam acetate (DB14671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral temazepam (10-20 mg)
Study: 405730
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg sodium aurothiomalate weekly
Study: 405730
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg sodium aurothiomalate weekly
Study: 28159194
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment of HTPR patients
Study: 21699697
Drug: CQ40 (extended
Approvals — FDA: no, EMA: no, PMDA: no
Description: CQ40 (extended five-day treatment at 40 mg/kg)
Study: 21699697
Drug: CQ25 (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: CQ25 (standard three-day treatment at 25 mg/kg)
Study: 19196886
Drug: Tadalafil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (10 mg o.d.)
Study: 16234834
Drug: Nucleotide-supplemented formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleotide-supplemented formula (33.5 mg/l)
Study: 16234834
Drug: Control formula
Normalized name: Anti Acne Control Formula Top
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control formula (10 mg/l NT)
Study: 9321530
Drug: cA2 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: cA2 (5 mg/kg)
Study: 8404750
Drug: Vigabatrin (VGB)
DrugBank: Vigabatrin (DB01080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vigabatrin (VGB) 1.0 g twice daily for 6 weeks, followed by 1.5 g twice daily for 6 weeks
Study: 8404750
Drug: Vigabatrin (VGB)
DrugBank: Vigabatrin (DB01080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vigabatrin (VGB) 2 g daily
Study: 8404750
Drug: Vigabatrin (VGB)
DrugBank: Vigabatrin (DB01080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vigabatrin (VGB) 3 g daily
Study: 31432705
Drug: Pembrolizumab in
Normalized name: pembrolizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab in first-line setting in combination with platinum doublets, any expression of PD-L1 (KEYNOTE-189 and KEYNOTE-407)
Study: 22309355
Drug: Teicoplanin loading
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin loading dose of 12 mg/kg body-weight (group B)
Study: 22309355
Drug: Teicoplanin loading
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin loading dose of 6 mg/kg body-weight (group A)
Study: 20649710
Drug: Fluconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (400 mg, single dose)
Study: 20649710
Drug: Clotrimazole (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole (twice daily)
Study: 15668287
Drug: docetaxel 30
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 30 mg/m(2) and irinotecan 60 mg/m(2) (days 1 and 8)
Study: 15668287
Drug: docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 75 mg/m(2) (day 1)
Study: 15668287
Drug: Combination arm
Normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination arm (docetaxel + irinotecan)
Study: 7901680
Drug: Beta-carotene (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (mean concentration 0.35 microgram/g in cases)
Study: 7901680
Drug: Alpha-tocopherol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-tocopherol (mean concentration 193 micrograms/g in cases)
Study: 7901680
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (mean beta-carotene concentration 0.42 microgram/g)
Study: 2877593
Drug: Vecuronium 0.015
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.015 + 0.085 mg/kg body weight at a 3 min interval
Study: 2877593
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of vecuronium 0.1 mg/kg body weight
Study: 27636144
Drug: Aprepitant plus
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant plus palonosetron (0.075 mg)
Study: 27636144
Drug: Aprepitant plus
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant plus ramosetron (0.3 mg)
Study: 24698672
Drug: Sorafenib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (400 mg, twice a day)
Study: 23955431
Drug: Ad35.CS.01 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad35.CS.01 vaccine at 10 (11) vp/mL
Study: 23955431
Drug: Ad35.CS.01 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad35.CS.01 vaccine at 10 (10) vp/mL
Study: 23955431
Drug: Ad35.CS.01 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad35.CS.01 vaccine at 10 (10) vp/mL and 10 (11) vp/mL
Study: 23955431
Drug: Ad35.CS.01 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad35.CS.01 vaccine (all doses)
Study: 19186342
Drug: Garcinia mangostana
Normalized name: GARCINIA MANGOSTANA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garcinia mangostana L. pericarp gel (GM gel) applied topically as an adjunct to periodontal treatment